The Experts below are selected from a list of 1674 Experts worldwide ranked by ideXlab platform

Maarten J Suttorp - One of the best experts on this subject based on the ideXlab platform.

  • tct 397 effect of post dilatation on device expansion and arterial healing following everolimus eluting Bioresorbable Stent absorb bvs versus durable polymer everolimus eluting metallic Stent ees implantation in stemi patients substudy of absorb stemi trofi ii
    Journal of the American College of Cardiology, 2016
    Co-Authors: Kyohei Yamaji, Andres Iniguez, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, Maarten J Suttorp, Lisette Okkels Jensen, Evald Hoj Christiansen, Gerritanne Van Es
    Abstract:

    Post-dilatation (PD) of Absorb BVS has been proposed to improve post-procedural angiographic and subsequent device related clinical outcomes. Whether this recommendation is also applicable among patients undergoing BVS implantation in the setting of primary PCI (PPCI) remains unknown. In the ABSORB

  • everolimus eluting Bioresorbable Stent vs durable polymer everolimus eluting metallic Stent in patients with st segment elevation myocardial infarction results of the randomized absorb st segment elevation myocardial infarction trofi ii trial
    European Heart Journal, 2016
    Co-Authors: Manel Sabate, Stephan Windecker, Andres Iniguez, Lisette Okkelsjensen, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, E H Christiansen, Maarten J Suttorp
    Abstract:

    Aims Patients with ST-segment elevation myocardial infarction (STEMI) feature thrombus-rich lesions with large necrotic core, which are usually associated with delayed arterial healing and impaired Stent-related outcomes. The use of Bioresorbable vascular scaffolds (Absorb) has the potential to overcome these limitations owing to restoration of native vessel lumen and physiology at long term. The purpose of this randomized trial was to compare the arterial healing response at short term, as a surrogate for safety and efficacy, between the Absorb and the metallic everolimus-eluting Stent (EES) in patients with STEMI. Methods and results ABSORB-STEMI TROFI II was a multicentre, single-blind, non-inferiority, randomized controlled trial. Patients with STEMI who underwent primary percutaneous coronary intervention were randomly allocated 1:1 to treatment with the Absorb or EES. The primary endpoint was the 6-month optical frequency domain imaging healing score (HS) based on the presence of uncovered and/or malapposed Stent struts and intraluminal filling defects. Main secondary endpoint included the device-oriented composite endpoint (DOCE) according to the Academic Research Consortium definition. Between 06 January 2014 and 21 September 2014, 191 patients (Absorb [ n = 95] or EES [ n = 96]; mean age 58.6 years old; 17.8% females) were enrolled at eight centres. At 6 months, HS was lower in the Absorb arm when compared with EES arm [1.74 (2.39) vs. 2.80 (4.44); difference (90% CI) −1.06 (−1.96, −0.16); P non-inferiority <0.001]. Device-oriented composite endpoint was also comparably low between groups (1.1% Absorb vs. 0% EES). One case of definite subacute Stent thrombosis occurred in the Absorb arm (1.1% vs. 0% EES; P = ns). Conclusion Stenting of culprit lesions with Absorb in the setting of STEMI resulted in a nearly complete arterial healing which was comparable with that of metallic EES at 6 months. These findings provide the basis for further exploration in clinically oriented outcome trials.

Andres Iniguez - One of the best experts on this subject based on the ideXlab platform.

  • tct 397 effect of post dilatation on device expansion and arterial healing following everolimus eluting Bioresorbable Stent absorb bvs versus durable polymer everolimus eluting metallic Stent ees implantation in stemi patients substudy of absorb stemi trofi ii
    Journal of the American College of Cardiology, 2016
    Co-Authors: Kyohei Yamaji, Andres Iniguez, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, Maarten J Suttorp, Lisette Okkels Jensen, Evald Hoj Christiansen, Gerritanne Van Es
    Abstract:

    Post-dilatation (PD) of Absorb BVS has been proposed to improve post-procedural angiographic and subsequent device related clinical outcomes. Whether this recommendation is also applicable among patients undergoing BVS implantation in the setting of primary PCI (PPCI) remains unknown. In the ABSORB

  • everolimus eluting Bioresorbable Stent vs durable polymer everolimus eluting metallic Stent in patients with st segment elevation myocardial infarction results of the randomized absorb st segment elevation myocardial infarction trofi ii trial
    European Heart Journal, 2016
    Co-Authors: Manel Sabate, Stephan Windecker, Andres Iniguez, Lisette Okkelsjensen, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, E H Christiansen, Maarten J Suttorp
    Abstract:

    Aims Patients with ST-segment elevation myocardial infarction (STEMI) feature thrombus-rich lesions with large necrotic core, which are usually associated with delayed arterial healing and impaired Stent-related outcomes. The use of Bioresorbable vascular scaffolds (Absorb) has the potential to overcome these limitations owing to restoration of native vessel lumen and physiology at long term. The purpose of this randomized trial was to compare the arterial healing response at short term, as a surrogate for safety and efficacy, between the Absorb and the metallic everolimus-eluting Stent (EES) in patients with STEMI. Methods and results ABSORB-STEMI TROFI II was a multicentre, single-blind, non-inferiority, randomized controlled trial. Patients with STEMI who underwent primary percutaneous coronary intervention were randomly allocated 1:1 to treatment with the Absorb or EES. The primary endpoint was the 6-month optical frequency domain imaging healing score (HS) based on the presence of uncovered and/or malapposed Stent struts and intraluminal filling defects. Main secondary endpoint included the device-oriented composite endpoint (DOCE) according to the Academic Research Consortium definition. Between 06 January 2014 and 21 September 2014, 191 patients (Absorb [ n = 95] or EES [ n = 96]; mean age 58.6 years old; 17.8% females) were enrolled at eight centres. At 6 months, HS was lower in the Absorb arm when compared with EES arm [1.74 (2.39) vs. 2.80 (4.44); difference (90% CI) −1.06 (−1.96, −0.16); P non-inferiority <0.001]. Device-oriented composite endpoint was also comparably low between groups (1.1% Absorb vs. 0% EES). One case of definite subacute Stent thrombosis occurred in the Absorb arm (1.1% vs. 0% EES; P = ns). Conclusion Stenting of culprit lesions with Absorb in the setting of STEMI resulted in a nearly complete arterial healing which was comparable with that of metallic EES at 6 months. These findings provide the basis for further exploration in clinically oriented outcome trials.

Angel Cequier - One of the best experts on this subject based on the ideXlab platform.

  • tct 397 effect of post dilatation on device expansion and arterial healing following everolimus eluting Bioresorbable Stent absorb bvs versus durable polymer everolimus eluting metallic Stent ees implantation in stemi patients substudy of absorb stemi trofi ii
    Journal of the American College of Cardiology, 2016
    Co-Authors: Kyohei Yamaji, Andres Iniguez, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, Maarten J Suttorp, Lisette Okkels Jensen, Evald Hoj Christiansen, Gerritanne Van Es
    Abstract:

    Post-dilatation (PD) of Absorb BVS has been proposed to improve post-procedural angiographic and subsequent device related clinical outcomes. Whether this recommendation is also applicable among patients undergoing BVS implantation in the setting of primary PCI (PPCI) remains unknown. In the ABSORB

  • everolimus eluting Bioresorbable Stent vs durable polymer everolimus eluting metallic Stent in patients with st segment elevation myocardial infarction results of the randomized absorb st segment elevation myocardial infarction trofi ii trial
    European Heart Journal, 2016
    Co-Authors: Manel Sabate, Stephan Windecker, Andres Iniguez, Lisette Okkelsjensen, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, E H Christiansen, Maarten J Suttorp
    Abstract:

    Aims Patients with ST-segment elevation myocardial infarction (STEMI) feature thrombus-rich lesions with large necrotic core, which are usually associated with delayed arterial healing and impaired Stent-related outcomes. The use of Bioresorbable vascular scaffolds (Absorb) has the potential to overcome these limitations owing to restoration of native vessel lumen and physiology at long term. The purpose of this randomized trial was to compare the arterial healing response at short term, as a surrogate for safety and efficacy, between the Absorb and the metallic everolimus-eluting Stent (EES) in patients with STEMI. Methods and results ABSORB-STEMI TROFI II was a multicentre, single-blind, non-inferiority, randomized controlled trial. Patients with STEMI who underwent primary percutaneous coronary intervention were randomly allocated 1:1 to treatment with the Absorb or EES. The primary endpoint was the 6-month optical frequency domain imaging healing score (HS) based on the presence of uncovered and/or malapposed Stent struts and intraluminal filling defects. Main secondary endpoint included the device-oriented composite endpoint (DOCE) according to the Academic Research Consortium definition. Between 06 January 2014 and 21 September 2014, 191 patients (Absorb [ n = 95] or EES [ n = 96]; mean age 58.6 years old; 17.8% females) were enrolled at eight centres. At 6 months, HS was lower in the Absorb arm when compared with EES arm [1.74 (2.39) vs. 2.80 (4.44); difference (90% CI) −1.06 (−1.96, −0.16); P non-inferiority <0.001]. Device-oriented composite endpoint was also comparably low between groups (1.1% Absorb vs. 0% EES). One case of definite subacute Stent thrombosis occurred in the Absorb arm (1.1% vs. 0% EES; P = ns). Conclusion Stenting of culprit lesions with Absorb in the setting of STEMI resulted in a nearly complete arterial healing which was comparable with that of metallic EES at 6 months. These findings provide the basis for further exploration in clinically oriented outcome trials.

Sjoerd H Hofma - One of the best experts on this subject based on the ideXlab platform.

  • tct 397 effect of post dilatation on device expansion and arterial healing following everolimus eluting Bioresorbable Stent absorb bvs versus durable polymer everolimus eluting metallic Stent ees implantation in stemi patients substudy of absorb stemi trofi ii
    Journal of the American College of Cardiology, 2016
    Co-Authors: Kyohei Yamaji, Andres Iniguez, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, Maarten J Suttorp, Lisette Okkels Jensen, Evald Hoj Christiansen, Gerritanne Van Es
    Abstract:

    Post-dilatation (PD) of Absorb BVS has been proposed to improve post-procedural angiographic and subsequent device related clinical outcomes. Whether this recommendation is also applicable among patients undergoing BVS implantation in the setting of primary PCI (PPCI) remains unknown. In the ABSORB

  • everolimus eluting Bioresorbable Stent vs durable polymer everolimus eluting metallic Stent in patients with st segment elevation myocardial infarction results of the randomized absorb st segment elevation myocardial infarction trofi ii trial
    European Heart Journal, 2016
    Co-Authors: Manel Sabate, Stephan Windecker, Andres Iniguez, Lisette Okkelsjensen, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, E H Christiansen, Maarten J Suttorp
    Abstract:

    Aims Patients with ST-segment elevation myocardial infarction (STEMI) feature thrombus-rich lesions with large necrotic core, which are usually associated with delayed arterial healing and impaired Stent-related outcomes. The use of Bioresorbable vascular scaffolds (Absorb) has the potential to overcome these limitations owing to restoration of native vessel lumen and physiology at long term. The purpose of this randomized trial was to compare the arterial healing response at short term, as a surrogate for safety and efficacy, between the Absorb and the metallic everolimus-eluting Stent (EES) in patients with STEMI. Methods and results ABSORB-STEMI TROFI II was a multicentre, single-blind, non-inferiority, randomized controlled trial. Patients with STEMI who underwent primary percutaneous coronary intervention were randomly allocated 1:1 to treatment with the Absorb or EES. The primary endpoint was the 6-month optical frequency domain imaging healing score (HS) based on the presence of uncovered and/or malapposed Stent struts and intraluminal filling defects. Main secondary endpoint included the device-oriented composite endpoint (DOCE) according to the Academic Research Consortium definition. Between 06 January 2014 and 21 September 2014, 191 patients (Absorb [ n = 95] or EES [ n = 96]; mean age 58.6 years old; 17.8% females) were enrolled at eight centres. At 6 months, HS was lower in the Absorb arm when compared with EES arm [1.74 (2.39) vs. 2.80 (4.44); difference (90% CI) −1.06 (−1.96, −0.16); P non-inferiority <0.001]. Device-oriented composite endpoint was also comparably low between groups (1.1% Absorb vs. 0% EES). One case of definite subacute Stent thrombosis occurred in the Absorb arm (1.1% vs. 0% EES; P = ns). Conclusion Stenting of culprit lesions with Absorb in the setting of STEMI resulted in a nearly complete arterial healing which was comparable with that of metallic EES at 6 months. These findings provide the basis for further exploration in clinically oriented outcome trials.

Lorenz Raber - One of the best experts on this subject based on the ideXlab platform.

  • tct 397 effect of post dilatation on device expansion and arterial healing following everolimus eluting Bioresorbable Stent absorb bvs versus durable polymer everolimus eluting metallic Stent ees implantation in stemi patients substudy of absorb stemi trofi ii
    Journal of the American College of Cardiology, 2016
    Co-Authors: Kyohei Yamaji, Andres Iniguez, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, Maarten J Suttorp, Lisette Okkels Jensen, Evald Hoj Christiansen, Gerritanne Van Es
    Abstract:

    Post-dilatation (PD) of Absorb BVS has been proposed to improve post-procedural angiographic and subsequent device related clinical outcomes. Whether this recommendation is also applicable among patients undergoing BVS implantation in the setting of primary PCI (PPCI) remains unknown. In the ABSORB

  • everolimus eluting Bioresorbable Stent vs durable polymer everolimus eluting metallic Stent in patients with st segment elevation myocardial infarction results of the randomized absorb st segment elevation myocardial infarction trofi ii trial
    European Heart Journal, 2016
    Co-Authors: Manel Sabate, Stephan Windecker, Andres Iniguez, Lisette Okkelsjensen, Angel Cequier, Salvatore Brugaletta, Sjoerd H Hofma, Lorenz Raber, E H Christiansen, Maarten J Suttorp
    Abstract:

    Aims Patients with ST-segment elevation myocardial infarction (STEMI) feature thrombus-rich lesions with large necrotic core, which are usually associated with delayed arterial healing and impaired Stent-related outcomes. The use of Bioresorbable vascular scaffolds (Absorb) has the potential to overcome these limitations owing to restoration of native vessel lumen and physiology at long term. The purpose of this randomized trial was to compare the arterial healing response at short term, as a surrogate for safety and efficacy, between the Absorb and the metallic everolimus-eluting Stent (EES) in patients with STEMI. Methods and results ABSORB-STEMI TROFI II was a multicentre, single-blind, non-inferiority, randomized controlled trial. Patients with STEMI who underwent primary percutaneous coronary intervention were randomly allocated 1:1 to treatment with the Absorb or EES. The primary endpoint was the 6-month optical frequency domain imaging healing score (HS) based on the presence of uncovered and/or malapposed Stent struts and intraluminal filling defects. Main secondary endpoint included the device-oriented composite endpoint (DOCE) according to the Academic Research Consortium definition. Between 06 January 2014 and 21 September 2014, 191 patients (Absorb [ n = 95] or EES [ n = 96]; mean age 58.6 years old; 17.8% females) were enrolled at eight centres. At 6 months, HS was lower in the Absorb arm when compared with EES arm [1.74 (2.39) vs. 2.80 (4.44); difference (90% CI) −1.06 (−1.96, −0.16); P non-inferiority <0.001]. Device-oriented composite endpoint was also comparably low between groups (1.1% Absorb vs. 0% EES). One case of definite subacute Stent thrombosis occurred in the Absorb arm (1.1% vs. 0% EES; P = ns). Conclusion Stenting of culprit lesions with Absorb in the setting of STEMI resulted in a nearly complete arterial healing which was comparable with that of metallic EES at 6 months. These findings provide the basis for further exploration in clinically oriented outcome trials.